How Pharmacists Can Make an Impact When Treating Dedifferentiated Liposarcoma With Brigimadlin
November 11th 2024Brigimadlin is a new oral MDM2-p53 antagonist under investigation as a potential first-line therapy to improve outcomes for patients with advanced or metastatic dedifferentiated liposarcoma.
Read More
Tackling the Growing Impact of Orphan Drug Designation and Limited Distribution Networks in Oncology
November 8th 2024Pharmacy teams are learning to adapt to the challenges of limited distribution networks and orphan drug designation in oncology, with integrated pharmacy support playing a crucial role in enhancing patient access and adherence.
Read More